Fatakhova Karina, Patel Pratik, Inayat Faisal, Dhillon Rubaid, Ali Hassam, Taj Sobaan, Nawaz Gul, Afzal Arslan, Rehman Attiq Ur, Afzal Muhammad Sohaib, Khan Rafeh, Ishtiaq Rizwan, Jones Lindsey, Rajapakse Ramona
Department of Gastroenterology, Mather Hospital and Hofstra University Zucker School of Medicine, Port Jefferson, New York.
Department of Medicine, Allama Iqbal Medical College, Lahore, Punjab, Pakistan.
Proc (Bayl Univ Med Cent). 2023 May 3;36(4):427-433. doi: 10.1080/08998280.2023.2204535. eCollection 2023.
Patients with inflammatory bowel disease (IBD) and substance use disorder (SUD) may have worse clinical outcomes. However, data specific to the hospital admission and mortality rates among IBD patients with SUD are scarce. Our objective was to assess trends in admission, healthcare expenses, and mortality for IBD patients with SUD.
We conducted a retrospective study using the National Inpatient Sample database to analyze SUD (alcohol, opioids, cocaine, and cannabis) among IBD hospitalizations from 2009 to 2019.
A total of 132,894 hospitalizations for IBD had a secondary diagnosis of SUD. Of these patients, 75,172 (57%) were men and 57,696 (43%) were women. The IBD-SUD cohort had a longer length of stay than the non-SUD cohort ( < 0.001). The mean inpatient charges for IBD hospitalizations with SUD increased from $48,699 ± $1374 in 2009 to $62,672 ± $1528 in 2019 ( < 0.001). We found a 159.5% increase in IBD hospitalizations with SUD. The hospitalization rate increased from 3492 per 100,000 IBD hospitalizations in 2009 to 9063 per 100,000 in 2019 ( < 0.001). In-hospital mortality for IBD hospitalizations with SUD increased by 129.6% (from 250 deaths per 100,000 IBD hospitalizations in 2009 to 574 deaths per 100,000 IBD hospitalizations in 2019) ( < 0.001).
Over the last decade, there has been a rise in IBD hospitalizations with SUD. This has resulted in a longer length of stay, higher inpatient charges, and higher mortality rates. Identifying IBD patients potentially at risk for SUD by screening for anxiety, depression, pain, or other factors has become crucial.
炎症性肠病（IBD）患者和物质使用障碍（SUD）患者可能有更差的临床结局。然而，关于患有SUD的IBD患者的住院率和死亡率的具体数据很少。我们的目的是评估患有SUD的IBD患者的住院趋势、医疗费用和死亡率。
我们使用国家住院样本数据库进行了一项回顾性研究，以分析2009年至2019年IBD住院患者中的SUD（酒精、阿片类药物、可卡因和大麻）情况。
共有132,894例IBD住院患者有SUD的二级诊断。在这些患者中，75,172例（57%）为男性，57,696例（43%）为女性。IBD-SUD队列的住院时间比非SUD队列更长（<0.001）。2009年患有SUD的IBD住院患者的平均住院费用为48,699美元±1374美元，到2019年增至62,672美元±1528美元（<0.001）。我们发现患有SUD的IBD住院患者增加了159.5%。住院率从2009年每10万例IBD住院患者中的3492例增至2019年的每10万例中的9063例（<0.001）。患有SUD的IBD住院患者的院内死亡率增加了129.6%（从2009年每10万例IBD住院患者中的250例死亡增至2019年的每10万例中的574例死亡）（<0.001）。
在过去十年中，患有SUD的IBD住院患者有所增加。这导致了更长的住院时间、更高的住院费用和更高的死亡率。通过筛查焦虑、抑郁、疼痛或其他因素来识别可能有SUD风险的IBD患者变得至关重要。
